BioPharmSignal logoBioPharmSignal

Biotech News

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics (VKTX)Viking TherapeuticsEarnings

VKTX (VKTX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is vktx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VKTXViking Therapeutics2026-07-29 20:05 EST

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-07-22 20:05 EST

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

MLYSMineralys Therapeutics2026-05-06 20:05 EST

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

CORTCorcept2026-04-30 20:05 EST

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

CORTCorcept2026-04-23 20:05 EST

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

ALGSAligos Therapeutics2026-05-07 20:06 EST

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

MLYSMineralys Therapeutics2026-04-29 20:05 EST

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

ALGSAligos Therapeutics2026-08-06 12:00 EST

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

BLTEBelite Bio2026-05-20 10:00 EST

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Viking Therapeutics

Obesity-Focused Metabolic Biotech Viking Therapeutics is a clinical-stage biotechnology company advancing therapies for obesity and metabolic disease. Its pipeline is led by VK2735 and supported by additional obesity, liver/metabolic, and rare disease programs. Lead Franchise: VK2735 VK2735 is a wholly owned dual GLP-1/GIP receptor...

Recent company news

VKTXViking Therapeutics2026-07-29 20:05 EST

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-07-23 11:05 EST

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

VKTXViking Therapeutics2026-07-22 20:05 EST

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

VKTXViking Therapeutics2026-06-24 11:05 EST

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

VKTXViking Therapeutics2026-06-11 11:05 EST

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

Stock data

Close
33.30 USD
Market cap
3.4B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States